Seungbeom Ko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Seungbeom Ko has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Gayong Shim
School of Systems Biomedical Science, Soongsil University, Seoul 06978, Republic of Korea
2 shared publications Hyejin Mun
College of Medicine, University of Oklahoma 3 Department of Oncology Science Oklahoma City, OK 73104
2 shared publications- Je-Hyun Yoon
University of Oklahoma
2 shared publications - Yu-Kyoung Oh
Seoul National University
2 shared publications Ahmet Eroglu
College of Medicine, University of Oklahoma 3 Department of Oncology Science Oklahoma City, OK 73104
1 shared publicationCari A. Sagum
The University of Texas MD Anderson Cancer Center 4 Department of Epigenetics and Molecular Carcinogenesis Houston, TX 77030
1 shared publication
Latest Publications
- Open Access
- 1 November 2024
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 137 (21)
Mature microRNA-binding protein QKI suppresses extracellular microRNA let-7b release
Argonaute (AGO), a component of RNA-induced silencing complexes (RISCs), is a representative RNA-binding protein (RBP) known to bind with mature microRNAs (miRNAs) and is directly involved in post-transcriptional gene silencing. However, despite the biological significance of miRNAs, the roles of other miRNA-binding proteins (miRBPs) remain unclear in the regulation of miRNA loading, dissociation from RISCs and extracellular release. In this study, we performed protein arrays to profile miRBPs and identify 118 RBPs that directly bind to miRNAs. Among those proteins, the RBP quaking (QKI) inhibits extracellular release of the mature microRNA let-7b by controlling the loading of let-7b into extracellular vesicles via additional miRBPs such as AUF1 (also known as hnRNPD) and hnRNPK. The enhanced extracellular release of let-7b after QKI depletion activates Toll-like receptor 7 (TLR7) and promotes the production of proinflammatory cytokines in recipient cells, leading to brain inflammation in the mouse cortex. Thus, this study reveals the contribution of QKI to the inhibition of brain inflammation via regulation of extracellular let-7b release.
- 1 November 2024
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 137 (21)
Open AccessMature microRNA-binding protein QKI suppresses extracellular microRNA let-7b release
Argonaute (AGO), a component of RNA-induced silencing complexes (RISCs), is a representative RNA-binding protein (RBP) known to bind with mature microRNAs (miRNAs) and is directly involved in post-transcriptional gene silencing. However, despite the biological significance of miRNAs, the roles of other miRNA-binding proteins (miRBPs) remain unclear in the regulation of miRNA loading, dissociation from RISCs and extracellular release. In this study, we performed protein arrays to profile miRBPs and identify 118 RBPs that directly bind to miRNAs. Among those proteins, the RBP quaking (QKI) inhibits extracellular release of the mature microRNA let-7b by controlling the loading of let-7b into extracellular vesicles via additional miRBPs such as AUF1 (also known as hnRNPD) and hnRNPK. The enhanced extracellular release of let-7b after QKI depletion activates Toll-like receptor 7 (TLR7) and promotes the production of proinflammatory cytokines in recipient cells, leading to brain inflammation in the mouse cortex. Thus, this study reveals the contribution of QKI to the inhibition of brain inflammation via regulation of extracellular let-7b release.
- 24 August 2022
- Published by Elsevier in Biomaterials
- Vol. 289, 121754
Blood-declustering excretable metal clusters assembled in DNA matrix
- 24 August 2022
- Published by Elsevier in Biomaterials
- Vol. 289, 121754
Blood-declustering excretable metal clusters assembled in DNA matrix
- Open Access
- 1 January 2022
- Published by XMLink in Journal of Lipid and Atherosclerosis
- Vol. 11 (1) , 55-72
Profiling of RNA-binding Proteins Interacting With Glucagon and Adipokinetic Hormone mRNAs
Ko S, et al. J Lipid Atheroscler. 2022 Jan;11(1):55-72. https://doi.org/10.12997/jla.2022.11.1.55
- 1 January 2022
- Published by XMLink in Journal of Lipid and Atherosclerosis
- Vol. 11 (1) , 55-72
Open AccessProfiling of RNA-binding Proteins Interacting With Glucagon and Adipokinetic Hormone mRNAs
Ko S, et al. J Lipid Atheroscler. 2022 Jan;11(1):55-72. https://doi.org/10.12997/jla.2022.11.1.55
- 19 March 2018
- Published by Tsinghua University Press in Nano Research
- Vol. 11 (4) , 2159-2172
Chemokine-mimetic plerixafor derivative for tumor-specific delivery of nanomaterials
Here, we report that chemokine-mimetic plerixafor derivatives could govern tumor-specific delivery and functional effects of nanomaterials. Reduced graphene oxide (rGO) nanosheets were used as a model functional nanomaterial, and plerixafor-conjugated lipid (PL/rGO) or a benzylcyclam derivative of plerixafor-conjugated lipid (BPL/rGO) was physically adsorbed onto the surface of rGO. The cellular uptake of surface-modified rGO was dependent on overexpression of the CXCR4 chemokine receptor on cancer cells. In KB cells, the binding affinity of BPL/rGO for CXCR4 was 6.8-fold greater than that of PL/rGO. Notably, cellular uptake patterns correlated with in vitro photothermal anticancer efficacy. The tumor distribution of BPL/rGO was higher than that of PL/rGO and plain rGO in mice bearing CXCR4-overexpressing tumors, whereas the distribution of the various rGO forms was similar in mice harboring CXCR4-negative tumors. Moreover, complete photothermal tumor ablation was observed in BPL/rGO-treated mice bearing CXCR4-positive KB cell tumors, but not in CXCR4-negative MCF-7 cell tumors. These results provide evidence that BPL can be used to enhance the delivery of nanomaterials to CXCR4-overexpressing tumors. Chemokine-mimetic BPL can be further applied for nanomaterial-based delivery of photosensitizers, anticancer drugs, or diagnostic tumor imaging agents in CXCR4-overexpressing cancer patients.
- 19 March 2018
- Published by Tsinghua University Press in Nano Research
- Vol. 11 (4) , 2159-2172
Chemokine-mimetic plerixafor derivative for tumor-specific delivery of nanomaterials
Here, we report that chemokine-mimetic plerixafor derivatives could govern tumor-specific delivery and functional effects of nanomaterials. Reduced graphene oxide (rGO) nanosheets were used as a model functional nanomaterial, and plerixafor-conjugated lipid (PL/rGO) or a benzylcyclam derivative of plerixafor-conjugated lipid (BPL/rGO) was physically adsorbed onto the surface of rGO. The cellular uptake of surface-modified rGO was dependent on overexpression of the CXCR4 chemokine receptor on cancer cells. In KB cells, the binding affinity of BPL/rGO for CXCR4 was 6.8-fold greater than that of PL/rGO. Notably, cellular uptake patterns correlated with in vitro photothermal anticancer efficacy. The tumor distribution of BPL/rGO was higher than that of PL/rGO and plain rGO in mice bearing CXCR4-overexpressing tumors, whereas the distribution of the various rGO forms was similar in mice harboring CXCR4-negative tumors. Moreover, complete photothermal tumor ablation was observed in BPL/rGO-treated mice bearing CXCR4-positive KB cell tumors, but not in CXCR4-negative MCF-7 cell tumors. These results provide evidence that BPL can be used to enhance the delivery of nanomaterials to CXCR4-overexpressing tumors. Chemokine-mimetic BPL can be further applied for nanomaterial-based delivery of photosensitizers, anticancer drugs, or diagnostic tumor imaging agents in CXCR4-overexpressing cancer patients.